Shanghai Henlius Biotech, Inc. announced that at its extraordinary general meeting held on 28 August 2023, approved the resolution in relation to the appointment of Mr. Jun Zhu as an executive director of the Company; approved the resolution in relation to the appointment of Dr. XINGLI WANG as a non-executive director of the Company.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
18.84 HKD | +4.67% | 0.00% | +35.54% |
05-24 | Organon, Henlius' Denosumab Biosimilar HLX14 Gets European Validation | MT |
05-24 | Henlius' EU Marketing Application for Denosumab Biosimilar Accepted and Validated by Regulator | MT |
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+35.54% | 1.31B | |
-2.91% | 89.01B | |
-3.68% | 37.79B | |
-14.91% | 31.22B | |
+60.33% | 26.1B | |
-22.74% | 14.25B | |
-8.73% | 12.8B | |
-10.57% | 11.65B | |
+4.04% | 8.7B | |
-17.54% | 7.45B |
- Stock Market
- Equities
- 2696 Stock
- News Shanghai Henlius Biotech, Inc.
- Shanghai Henlius Biotech, Inc. Announces Executive Appointments